Dr. Daniel Zainfeld, M.D.
What this data tells you about Dr. Zainfeld
Dr. Daniel Zainfeld is an urology physician in San Antonio, TX, with 14 years of NPI registration. Based on federal Medicare data, Dr. Zainfeld performed 4,041 Medicare services across 2,159 unique beneficiaries.
Between the years covered by Open Payments, Dr. Zainfeld received a total of $17,867 from 16 pharmaceutical and/or device companies across 59 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zainfeld is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Infectious disease DNA/RNA test | 941 | $34 | $78 |
| Urinalysis with microscopic exam | 538 | $3 | $15 |
| Office visit, established patient (20-29 min) | 327 | $60 | $150 |
| Office visit, established patient (30-39 min) | 258 | $90 | $215 |
| Blood draw (venipuncture) | 232 | $8 | $10 |
| Chronic care management, first 20 min/month | 222 | $43 | $82 |
| Diagnostic exam of bladder and urethra using an endoscope | 135 | $175 | $490 |
| Bladder ultrasound after voiding | 131 | $7 | $95 |
| PSA test (prostate cancer screening) | 118 | $18 | $110 |
| Cell examination of specimen, selective cellular enhancement technique | 109 | $26 | $210 |
| Yeast/candida DNA test | 78 | $34 | $78 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 78 | $34 | $78 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 78 | $34 | $78 |
| Basic metabolic blood panel | 75 | $8 | $45 |
| Testosterone (hormone) level, total | 59 | $25 | $150 |
| New patient office visit (45-59 min) | 58 | $105 | $313 |
| Instillation, hexaminolevulinate hydrochloride, 100 mg | 58 | $972 | $2,410 |
| Complete blood count (CBC) with differential | 50 | $8 | $25 |
| Complete blood count (CBC), automated | 47 | $6 | $25 |
| Instillation of anti-cancer drug into bladder | 44 | $65 | $270 |
| Blood creatinine level | 40 | $5 | $20 |
| Urea nitrogen level to assess kidney function, quantitative | 39 | $4 | $20 |
| Ct scan of abdomen and pelvis before and after contrast | 32 | $255 | $700 |
| Complete ultrasound scan behind abdominal cavity | 30 | $76 | $345 |
| New patient office visit (30-44 min) | 26 | $76 | $210 |
| Hospital follow-up visit, low complexity | 26 | $38 | $90 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 25 | $128 | $751 |
| Biopsy of prostate gland | 24 | $87 | $350 |
| Ultrasound scan of pelvic region through rectum | 24 | $24 | $285 |
| Pathology examination of tissue using a microscope, moderately high complexity | 23 | $158 | $575 |
| Ct scan of chest with contrast | 20 | $77 | $600 |
| Tissue pathology examination, moderate complexity | 17 | $26 | $65 |
| Insertion of stent in ureter using an endoscope | 16 | $105 | $1,350 |
| Destruction and/or removal of large growth of bladder using an endoscope | 14 | $294 | $2,350 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 13 | $175 | $1,150 |
| Initial hospital admission, moderate complexity | 13 | $100 | $275 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 12 | $63 | $165 |
| Microscopic genetic analysis of tumor, manual | 11 | $58 | $250 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (50%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Zainfeld is a clinical cardiology specialist, with above-average Medicare volume (top 30% in TX), with consulting-driven industry engagement in the top 13% of TX peers.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Zainfeld experienced with infectious disease dna/rna test?
Does Dr. Zainfeld receive payments from pharmaceutical companies?
How do Dr. Zainfeld's costs compare to other urology physicians in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology